Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus

Published:2015-04-15 Issue:7 Volume:17 Page:665-674
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Araki E.¹,Tanizawa Y.²,Tanaka Y.³,Taniguchi A.³,Koiwai K.³,Kim G.⁴,Salsali A.⁵,Woerle H. J.⁴,Broedl U. C.⁴

Affiliation:

1. Department of Metabolic Medicine; Kumamoto University; Kumamoto Japan

2. Division of Endocrinology; Yamaguchi University Graduate School of Medicine; Ube Yamaguchi Japan

3. Nippon Boehringer Ingelheim Co., Ltd; Tokyo Japan

4. Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim Germany

5. Boehringer Ingelheim Pharmaceuticals, Inc.; Ridgefield CT USA

Funder

Boehringer Ingelheim

Eli Lilly and Company

Mitsubishi Tanabe

Sanofi

Astellas

Dainippon Sumitomo

Pfizer

MSD

Kowa Pharmaceutical

Takeda

Daiichi Sankyo

Kyowa Hakko Kirin

Novartis

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12464/fullpdf

Reference21 articles.

1. Diabetes in Japan: a review of disease burden and approaches to treatment;Neville;Diabetes Metab Res Rev,2009

2. Global estimates of diabetes prevalence for 2013 and projections for 2035;Guariguata;Diabetes Res Clin Pract,2014

3. Japan Diabetes Society Treatment guide for diabetes 2014-2015 (in Japanese) http://www.jds.or.jp/modules/en/index.php?content_id=34

4. Changes in oral antidiabetic prescriptions and improved glycemic control during the years 2002-2011 in Japan (JDDM32);Oishi;J Diabetes Invest,2014

5. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospect Diabetes Study (UKPDS) Group;Turner;JAMA,1999

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A meta‐analysis of randomized controlled studies examining the effects of sodium‐glucose co‐transporter‐2 inhibitors on peripheral artery disease and risk of amputations;Diabetes, Obesity and Metabolism;2024-09-12

2. First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis;Frontiers in Endocrinology;2024-01-29

3. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin;Diabetes Therapy;2023-11-14

4. Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY);Diabetes, Obesity and Metabolism;2023-08-25

5. Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: a meta-analysis of randomized controlled trials;Cardiovascular Diabetology;2023-03-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3